Tbio ADARB1 Double-stranded RNA-specific editase 1

Protein Summary

Description

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. This gene encodes the enzyme responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. Studies in rat found that this enzyme acted on its own pre-mRNA molecules to convert an AA dinucleotide to an AI dinucleotide which resulted in a new splice site. Alternative splicing of this gene results in several transcript variants, some of which have been characterized by the presence or absence of an ALU cassette insert and a short or long C-terminal region. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• P78563
• A6NFK8
• A6NJ84
• C3TTQ1
• C3TTQ2
• C9JUP4
• G5E9B4
• O00395
• O00465
• O00691
• O00692
• P78555
• Q4AE77
• Q4AE79
• Q6P0M9
• Q8NFA1
• Q8NFD1

Gene Name

• ADARB1

Ensembl ID

• ENST00000348831
• ENSP00000015877
• ENSG00000197381
• ENST00000360697
• ENSP00000353920
• ENST00000389863
• ENSP00000374513
• ENST00000437626
• ENSP00000414600
• ENST00000492414
• ENSP00000436367
• ENST00000496664
• ENSP00000435381
• ENST00000629643
• ENSP00000486475

Symbol

• ADAR2
• DRADA2
• RED1
• RED1
• ADAR2
• DRABA2
• DRADA2

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
kinase perturbation	0.95
microRNA	0.86
transcription factor perturbation	0.84
disease perturbation	0.83
biological process	0.71

Protein Classes

PANTHER Classes

Protein / Nucleic Acid Binding / Rna Binding Protein / Double-stranded Rna-specific Editase 1

Protein / Nucleic Acid Binding / Dna Binding Protein / Double-stranded Rna-specific Editase 1

Protein / Hydrolase / Deaminase / Double-stranded Rna-specific Editase 1

Protein / Enzyme Modulator / Kinase Modulator / Kinase Activator / Double-stranded Rna-specific Editase 1

Protein / Defense/immunity Protein / Double-stranded Rna-specific Editase 1

DTO Classes

Protein / Enzyme / Hydrolase / Deaminase / Double-stranded Rna-specific Editase 1

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 213.83   (req: < 5)

Gene RIFs: 73   (req: <= 3)

Antibodies: 121   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 213.83   (req: >= 5)

Gene RIFs: 73   (req: > 3)

Antibodies: 121   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 27

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0